Overview
Bioscience company's Q4 net sales rose 16%, beating analyst expectations
Net income for Q4 declined due to higher operating expenses
Gross margin improved 160 bps to 64.1% in Q4
Outlook
Niagen Bioscience expects 2026 net sales to grow 10-15% year-over-year
Company anticipates slight improvement in gross margin for 2026
Result Drivers
TRU NIAGEN SALES - Q4 sales increased 21%, driven by e-commerce growth
GROSS MARGIN IMPROVEMENT - Improved 160 bps due to lower-cost inventory and better labor utilization
HIGHER OPERATING EXPENSES - Q4 net income affected by increased operating expenses, despite royalty settlement gains
Company press release: ID:nBw14YmWFa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Sales | Beat | $33.8 mln | $31.70 mln (5 Analysts) |
Q4 Net Income | $4.1 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Niagen Bioscience Inc is $14.00, about 187.5% above its March 3 closing price of $4.87
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 24 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)